German Federal Joint Committee (G-BA)

11

Jan 2021

In late December 2020, the Innovation Committee at the Federal Joint Committee (G-BA) has announced funding from the G-BA Innovation Fund of twenty-eight innovative projects on new forms of medical care. Read more

26

Nov 2020

On November 9, 2020, in accordance with §137h Paragraph 6 SGB V, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for endovascular implantation of a stent-graft with valve element in tricuspid valve insufficiency within the framework of the early benefit assessment. Read more

28

Oct 2020

In mid-October 2020, the Federal Joint Committee (G-BA) has decided that three more biomarker-based tests in breast cancer will be covered by the statutory health insurance. Since January 2020, the "Oncotype DX Breast Recurrence Score" test is already reimbursed in Germany with a tariff of €3,296.50. Read more

30

Jul 2020

In late June 2020, the Innovation Committee at the Federal Joint Committee (G-BA) published funding priorities on its website. For the first time, the decision on the funding priorities was preceded by a consultation process. Healthcare stakeholders who are not members of the Innovation Committee were asked to come up with suggestions for funding topics and criteria. Read more

14

May 2020

The corresponding decision by the (the Federal Joint Committee) of January 16, 2020, was published in the Federal Gazette and came into force on April 9, 2020. Read more

23

Apr 2020

The revised EBM (German Uniform Evaluation Standard) comes into force on April 1, 2020. Among others, the amendments made concern the billing of the services within the framework of early detection of cervical cancer. Also, the new fee order item (GOP) for the human papillomaviruses (HPV) genotyping service was added. Read more

16

Apr 2020

Patients with a newly diagnosed glioblastoma will have an opportunity to benefit from the therapy with tumor-treating fields (TTF) at the expense of statutory health insurance. The Federal Joint Committee (G-BA) decided on March 20, 2020, the details concerning the indications and the quality assurance measures that will apply when prescribing this outpatient treatment method. Read more

09

Apr 2020

Balneophototherapy becomes covered by the National Association of Statutory Health Insurance Funds (GKV) for patients suffering from moderate to severe neurodermatitis. The Federal Joint Committee (G-BA) decided to include this treatment option to contract medical care on March 20, 2020. Read more

12

Mar 2020

In severe cases of lipedema, the costs for liposuction will be covered by the statutory health insurance companies from January 2020. The National Association of Statutory Health Insurance Physicians (KBV) and the National Association of Statutory Health Insurance Funds (GKV) have added several new fee order items to the EBM (German Uniform Evaluation Standard) and set the reimbursement. Read more

27

Feb 2020

On the 17th of February 2020, the Innovation Committee at the Federal Joint Committee (G-BA) invited external stakeholders to suggest topics and criteria for future funding. Moreover, the submission of proposals for members of the new pool of experts was announced. Read more

24

Feb 2020

The patients diagnosed with osteoporosis requiring medication will be able to receive care within a structured treatment program (disease management program, DMP). The Federal Joint Committee (G-BA) decided in mid-January 2020 the details of participation and the various aspects of care. Read more

06

Feb 2020

The Federal Joint Committee (G-BA) has updated the nationwide requirements for disease management programs (DMP) for patients with type 1 diabetes mellitus. The current DMP contracts must then be adjusted to the new requirements within one year of the decision coming into force. Around 225,000 legally insured patients are currently enrolled in a DMP for type 1 diabetes. Read more